TG Therapeutics Inc. stocks have been trading up by 9.62 percent following highly positive coverage of its multiple sclerosis therapy.
What Traders Need To Know
- Q2 2026 revenue hit about $240M, with U.S. BRIUMVI sales up 64% year over year to $227.7M, topping expectations near $229.8M.
- Management lifted 2026 total revenue guidance to around $950M and BRIUMVI U.S. sales to $890–$905M, targeting roughly a $1B annualized U.S. run rate by late 2026.
- Despite higher spending on subcutaneous BRIUMVI and pipeline work, TG Therapeutics Inc. stayed profitable and finished Q2 with $612M in cash.
- Q2 EPS of $0.05 missed estimates that ranged from $0.31 to $0.44, triggering a 10.6% slide to $46.52 on the earnings reaction.
- A price‑target hike to $86, strong Buy‑side sentiment, and buyout rumors helped the stock rebound about 4% to $52.82, adding speculative fuel.
Weekly Update Aug 17 – Aug 21, 2026: On Saturday, August 22, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 9.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
TG Therapeutics sits in a strong but richly valued commercial-stage position anchored by BRIUMVI. Revenue of ~$616M and three‑year growth above 220% place it in the top decile of SMID-cap biotech, with exceptional 92.7% gross margin and positive EBIT margin (~11%). ROE and ROIC are unusually high, aided by stock-based comp and NOLs, while leverage (D/E 1.25, interest cover 2.5) is acceptable given a 4.3x current ratio and nearly $0.5B cash.
Technically, TGTX is in a clear short-term uptrend, breaking from ~$49 to >$55 this week and closing near highs, confirming aggressive dip-buying after the post-earnings pullback. Five‑minute tape shows sustained bid density on pushes through $51–52 with rising volume, suggesting new institutional interest rather than short covering alone. The key actionable level is $52: above it, risk-on long positioning toward $60 is favored; loss of $49 would invalidate this near-term bull setup.
More Breaking News
- Pinterest Stock Slips As Revenue Misses Rattle Traders
- No Analysis Provided
- Rocket Companies RKT Stock Dips As Q3 Earnings Smash Estimates
- Micron Stock Slides As China’s CXMT DRAM Threat Rattles Traders
Fundamentally and versus biotech benchmarks, TGTX now trades as a profitable growth franchise, not a speculative development name. Guidance to ~$950M 2026 revenue and exiting 2026 at a ~$1B BRIUMVI U.S. run rate materially exceeds typical mid-cap peers, while cash of ~$612M funds subcutaneous and label-expansion programs. Takeout chatter provides incremental optionality, but the core driver is sustained MS execution. I see fair value at $70 within 12–18 months, with support ~$49 and resistance ~$60 then ~$70.
Quick Financial Overview
TG Therapeutics Inc. is now a scaled commercial story, not just a development‑stage biotech. Q2 2026 revenue of about $240M, driven by $227.7M in U.S. BRIUMVI sales, shows a steep ramp, with total revenue up roughly 70% year over year. Management’s move to raise 2026 revenue guidance to around $950M, and to target an exit 2026 BRIUMVI U.S. run rate near $1B, signals strong confidence in demand.
Profitability is positive but still thin, which matters for traders watching earnings quality. Net income from continuing operations was about $7.8M, or $0.05 per share, well below Street expectations, which explains the sharp post‑earnings selloff. Margins are mixed: gross margin is extremely high at 92.7%, but EBIT margin is only 11.3%, and heavy R&D and SG&A tied to subcutaneous BRIUMVI and pipeline expansion are keeping EPS under pressure.
The balance sheet gives TG Therapeutics Inc. room to execute. Cash and equivalents sit near $483.9M, with total cash and short‑term investments around $552.2M, versus long‑term debt of about $752.5M. Liquidity ratios are strong, with a current ratio of 4.3 and quick ratio of 3.6, so near‑term funding risk is low. Valuation is rich, with a P/E near 18.5 and price‑to‑sales around 9.7, meaning the market already prices in continued growth and pipeline success.
On the chart, TGTX has shown strong near‑term momentum with pronounced volatility. Weekly data show a steady push from roughly $49 to above $55 over a short window, with higher highs and higher closes pointing to active dip‑buying. An intraday spike that ran from just above $51 to nearly $56.9 before closing around $54.3 shows aggressive demand on headline‑driven flows, but also intraday swings that can punish loose risk control.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.